retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial Eli Lilly's shows promising weight loss results in 3 Retatrutide Explained: How the Triple

This means you do not reach the full therapeutic dose until roughly month four or five

PurpleLab, using its healthcare claims database and HealthNexus analytics platform, analyzed medical and pharmacy claims for 12.2M people taking GLP-1 medications from January 2019 May 2024

The intervention group consisted of patients who were prescribed GLP-1 RA medications, including Victoza (Liraglutide 1.8 mg), Saxenda (Liraglutide 3 mg), Ozempic (Semaglutide 1 mg), and Wegovy (Semaglutide 2.4 mg)

95% CI: 00.11) were associated with significantly lower fracture risk, whereas trelagliptin (a DPP-4 inhibitor) was linked to increased fracture risk (RR = 3.51

S., DiMarchi, R

Clinical trials have shown that these medications reduce the risk of major cardiovascular events, including heart attack and stroke